Cancer Conversations™ in MCL: Experts Discuss Evolving Treatment Paradigms and Ongoing Clinical Trials

Download All
Gain expert insight on optimal management approaches to mantle cell lymphoma with an on-demand webinar, expert-authored commentary, downloadable slides, and an updated Interactive Decision Support Tool with expert recommendations for your specific patient scenarios.
Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS
John P. Leonard, MD

ClinicalThought

Mantle cell lymphoma is one of the most challenging lymphomas to manage. In this commentary, I share how I incorporate disease characteristics and patient preferences to select therapy in the frontline setting and beyond.

John P. Leonard, MD Released: July 29, 2021

Downloadable Slidesets

Download these slides from a live webinar to learn more about the current treatment paradigm for mantle cell lymphoma and ongoing trials poised to change the treatment landscape.

Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS John P. Leonard, MD
Released: August 24, 2021

Download this summary slideset from a live webinar for a quick overview of the evolving treatment paradigm for mantle cell lymphoma.

Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS John P. Leonard, MD
Released: August 26, 2021

On-Demand Webcast

Watch this on-demand webcast of a live CCO webinar to hear a panel of experts discuss the current treatment landscape and ongoing clinical trials in mantle cell lymphoma.

Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS John P. Leonard, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue